Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fortress Biotech (Nasdaq: FBIO), an innovative biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Lindsay A. Rosenwald, M.D., the company's Chairman, President, and CEO, will present a corporate overview at the event. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.
Fortress Biotech focuses on acquiring and advancing assets to enhance long-term shareholder value through various revenue streams, including product revenue, equity holdings, and dividend and royalty revenue. The company will also participate in one-on-one meetings during the conference, providing an opportunity for more in-depth discussions with investors and industry professionals.
Fortress Biotech (Nasdaq: FBIO), un'azienda biopharmaceutica innovativa, ha annunciato la sua partecipazione alla 26a Conferenza Annuale degli Investimenti Globali H.C. Wainwright. Lindsay A. Rosenwald, M.D., il presidente, CEO e chairman dell'azienda, presenterà una panoramica aziendale durante l'evento. La presentazione sarà disponibile per la visione on-demand per i partecipanti alla conferenza a partire dal 9 settembre 2024, alle 7:00 ET.
Fortress Biotech si concentra sull'acquisizione e sullo sviluppo di asset per migliorare il valore a lungo termine per gli azionisti attraverso vari flussi di entrate, inclusi i ricavi da prodotto, le partecipazioni azionarie e i ricavi da dividendi e royalties. L'azienda parteciperà anche a incontri one-on-one durante la conferenza, offrendo l'opportunità per discussioni più approfondite con investitori e professionisti del settore.
Fortress Biotech (Nasdaq: FBIO), una empresa biofarmacéutica innovadora, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright. Lindsay A. Rosenwald, M.D., el presidente, director ejecutivo y chairman de la empresa, presentará una visión general corporativa en el evento. La presentación estará disponible para visualización a demanda para los asistentes a la conferencia a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET.
Fortress Biotech se centra en la adquisición y el avance de activos para mejorar el valor a largo plazo de los accionistas a través de diversas fuentes de ingresos, incluidos los ingresos por productos, las participaciones de capital y los ingresos por dividendos y regalías. La empresa también participará en reuniones uno a uno durante la conferencia, ofreciendo la oportunidad de discusiones más profundas con inversores y profesionales de la industria.
Fortress Biotech (Nasdaq: FBIO), 혁신적인 생명공학 제약 회사,는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. Lindsay A. Rosenwald, M.D., 회사의 회장 겸 CEO는 행사에서 기업 개요를 발표할 예정입니다. 발표는 주문형 시청이 가능하며, 컨퍼런스 참석자는 2024년 9월 9일 오전 7시(ET)부터 시청할 수 있습니다.
Fortress Biotech는 자산을 인수하고 발전시키는 것에 집중하여 제품 수익, 지분 보유 및 배당금 및 로열티 수익을 포함한 다양한 수익원을 통해 장기 주주 가치를 높이고자 합니다. 회사는 또한 컨퍼런스 동안 일대일 미팅에 참여하여 투자자 및 업계 전문가와 더 심도 있는 논의의 기회를 제공합니다.
Fortress Biotech (Nasdaq: FBIO), une entreprise biopharmaceutique innovante, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Lindsay A. Rosenwald, M.D., le président, directeur général et président de l'entreprise, présentera un aperçu de l'entreprise lors de l'événement. La présentation sera disponible pour une visualisation à la demande pour les participants à la conférence à partir du 9 septembre 2024 à 7h00 ET.
Fortress Biotech se concentre sur l'acquisition et le développement d'actifs afin d'améliorer la valeur à long terme pour les actionnaires grâce à diverses sources de revenus, y compris les revenus des produits, les participations et les revenus provenant des dividendes et des redevances. L'entreprise participera également à des réunions individuelles durant la conférence, offrant l'occasion de discussions plus approfondies avec des investisseurs et des professionnels du secteur.
Fortress Biotech (Nasdaq: FBIO), ein innovatives biopharmazeutisches Unternehmen, hat seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright angekündigt. Lindsay A. Rosenwald, M.D., der Vorsitzende, Präsident und CEO des Unternehmens, wird bei der Veranstaltung eine Unternehmensübersicht präsentieren. Die Präsentation wird für on-demand Betrachtung für die Konferenzteilnehmer ab 9. September 2024 um 7:00 Uhr ET verfügbar sein.
Fortress Biotech konzentriert sich auf die Akquisition und Weiterentwicklung von Vermögenswerten, um den langfristigen Unternehmenswert durch verschiedene Einnahmequellen zu steigern, einschließlich Produktumsatz, Beteiligungen und Einnahmen aus Dividenden und Lizenzgebühren. Das Unternehmen wird auch an eins-zu-eins-Meetings während der Konferenz teilnehmen, um eine Gelegenheit zu tiefergehenden Gesprächen mit Investoren und Branchenprofis zu bieten.
- None.
- None.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Fortress Biotech (FBIO) present at the H.C. Wainwright Global Investment Conference?
Who will be presenting on behalf of Fortress Biotech (FBIO) at the conference?
What is the focus of Fortress Biotech (FBIO) as a company?
Will Fortress Biotech (FBIO) be conducting one-on-one meetings at the H.C. Wainwright conference?
